

Pharmaceutical Management Agency  
New Zealand  
Pharmaceutical Schedule

# Section H Update

for Hospital Pharmaceuticals

**July 2021**



**PHARMAC**  
TE PĀTAKA WHAIORANGA

## **Contents**

Summary of decisions effective 1 July 2021 .....	3
Section H changes to Part II .....	8
Index .....	16

## Summary of decisions

EFFECTIVE 1 JULY 2021

- Acarbose (Accarb) tab 50 mg and 100 mg – new listing and addition of PSS
- Acarbose (Glucobay) tab 50 mg and 100 mg – to be delisted 1 December 2021
- Amikacin (DBL Amikacin) inj 250 mg per ml, 2 ml vial – price decrease and addition of PSS
- Amino acid formula (Alfamino) powder 13.3 g protein, 57 g carbohydrate and 24.6 g fat per 100 g, can – new listing
- Amoxicillin with clavulanic acid (Amoxiclav multichem) inj 500 mg with clavulanic acid 100 mg vial and inj 1,000 mg with clavulanic acid 200 mg vial – new listing and addition of PSS
- Amoxicillin with clavulanic acid (m-Amoxiclav) inj 500 mg with clavulanic acid 100 mg vial and inj 1,000 mg with clavulanic acid 200 mg vial – to be delisted 1 December 2021
- Aprepitant (Emend Tri-pack) cap 2 x 80mg and 1 x 125 mg – price decrease and addition of PSS
- Articaine hydrochloride with adrenaline (Any Brand) inj 4% with adrenaline 1:100,000 and inj 4% with adrenaline 1:200,000, 1.8 ml dental cartridge – new listings
- Atorvastatin (Lorstat) tab 10 mg, 20 mg, 40 mg and 80 mg – price decrease and addition of PSS
- Azacitidine (Azacitidine Dr Reddy's) inj 100 mg vial – price decrease and addition of PSS
- Azithromycin (Zithromax) tab 500 mg – new listing and addition of HSS
- Azithromycin (Apo-Azithromycin) tab 500 mg – to be delisted 1 December 2021
- Baclofen (Medsurge) inj 2 mg per ml, 5 ml ampoule – price decrease and addition of PSS
- Betamethasone dipropionate with calcipotriol (Daviobet) gel 500 mcg with calcipotriol 50 mcg per g, 60 g and oint 500 mcg with calcipotriol 50 mcg per g, 30 g – price decrease and addition of PSS
- Bisacodyl (Lax-Suppositories) suppos 10 mg – price decrease and addition of PSS
- Bosentan (Bosentan Dr Reddy's) tab 62.5 mg and 125 mg – price decrease and addition of PSS
- Candesartan (Candestar) tab 4 mg – price increase and addition of PSS
- Candesartan (Candestar) tab 8 mg – addition of PSS
- Candesartan (Candestar) tab 16 mg and 32 mg – price decrease and addition of PSS

## Summary of decisions – effective 1 July 2021 (continued)

- Crotamiton (Itch-Soothe) crm 10%, 20 g – addition of PSS
- Cyclizine hydrochloride (Nausicalm) tab 50 mg – price decrease and addition of PSS
- Cyclophosphamide (Endoxan) inj 1 g vial and 2 g vial – addition of PSS
- Dobutamine (Dobutamine-hameln) inj 12.5 mg per ml, 20 ml ampoule – addition of PSS
- Dorzolamide with timolol (Dortimopt) eye drops 2% with timolol 0.5%, 5 ml – price decrease and addition of PSS
- Doxazosin (Apo-Doxazosin) tab 2 mg and 4 mg – price increase
- Enoxaparin sodium inj 20 mg in 0.2 ml syringe, 40 mg in 0.4 ml syringe, 60 mg in 0.6 ml syringe, 80 mg in 0.8 ml syringe and 100 mg in 1 ml syringe (Clexane) and inj 120 mg in 0.8 ml syringe and 150 mg in 1 ml syringe (Clexane Forte) – price increase
- Febuxostat (Adenuric) tab 80 mg and 120 mg – amended restriction criteria
- Ferrous sulfate (Ferrograd) tab long-acting 325 mg (105 mg elemental) – chemical name change
- Ferrous sulfate with ascorbic acid tab long-acting 325 mg (105 mg elemental) with ascorbic acid 500 mg – chemical name change
- Filgrastim (Nivestim) inj 300 mcg in 0.5 ml prefilled syringe – addition of PSS
- Filgrastim (Nivestim) inj 480 mcg in 0.5 ml prefilled syringe – price decrease and addition of PSS
- Fluorouracil sodium (Efudix) crm 5%, 20 g – price decrease and addition of PSS
- Folic acid (Folic Acid Mylan) tab 5 mg – new listing and addition of HSS
- Folic acid (Apo-Folic Acid) tab 5 mg – to be delisted 1 December 2021
- Fluconazole (Fluconazole-Baxter) inj 2 mg per ml, 50 ml vial – new listing and addition of HSS
- Fluconazole (Fluconazole-Claris) inj 2 mg per ml, 50 ml vial – removal of HSS
- Fluticasone propionate (Flixonase Hayfever & Allergy) nasal spray 50 mcg per dose – addition of PSS
- Gadoteric acid (Dotarem) inj 279.32 mg per ml (0.5 mmol per ml), 10 ml prefilled syringe, 15 ml prefilled syringe, 20 ml prefilled syringe, 5 ml bottle, 10 ml bottle, 15 ml bottle and 20 ml bottle – price decrease
- Gadoteric acid (Dotarem) inj 279.32 mg per ml (0.5 mmol per ml), 10 ml prefilled syringe, 15 ml prefilled syringe and 20 ml prefilled syringe, 10 inj pack – new listing

## **Summary of decisions – effective 1 July 2021 (continued)**

- Gadoteric acid (Dotarem) inj 279.32 mg per ml (0.5 mmol per ml), 10 ml prefilled syringe, 15 ml prefilled syringe and 20 ml prefilled syringe, 1 inj pack – to be delisted 1 July 2022
- Hydrocortisone butyrate oint 0.1%, 100 g (Locoid), scalp lotn 0.1%, 100 ml (Locoid) and milky emul 0.1%, 100 ml (Locoid Crelo) – price decrease and addition of PSS
- Hydrocortisone with miconazole (Micreme H) crm 1% with miconazole nitrate 2%, 15 g – price decrease and addition of PSS
- Imatinib mesilate tab 100 mg (Glivec) and cap 100 mg and 400 mg (Imatinib-Rex) – amended note
- Iron (as ferric carboxymaltose) (Ferinject) inj 50 mg per ml, 10 ml vial – chemical name change
- Iron (as sucrose) (Venofer) inj 20 mg per ml, 5 ml ampoule – chemical name change
- Lansoprazole (Lanzol Relief) cap 15 mg and 30 mg – price decrease and addition of PSS
- Lidocaine [Lignocaine] hydrochloride (Lidocaine-Baxter) inj 2%, 5 ml ampoule and 20 ml vial – new listing and addition of HSS
- Lidocaine [Lignocaine] hydrochloride (Lidocaine-Claris) inj 2%, 5 ml ampoule – to be delisted 1 January 2022 and removal of HSS
- Linezolid (Linezolid Kabi) inj 2 mg per ml, 300 ml bottle, 10 inj pack – new listing and addition of PSS
- Linezolid (Linezolid Kabi) inj 2 mg per ml, 300 ml bottle, 1 inj pack – to be delisted 1 December 2021
- Linezolid (Zyvox) tab 600 mg – price decrease and addition of PSS
- Lorazepam (Ativan) tab 1 mg and 2.5 mg – addition of PSS
- Meningococcal B multicomponent vaccine (Bexsero) inj 175 mcg per 0.5 ml prefilled syringe, 1 pack – new listing and access criteria apply
- Mepivacaine hydrochloride with adrenaline (Any Brand) inj 2% with adrenaline 1:100,000, 1.8 ml and 2.2 ml dental cartridge – new listings
- Mexiletine hydrochloride (Teva) cap 150 mg and 250 mg – new listing
- Mexiletine hydrochloride (Mexiletine Hydrochloride USP) cap 150 mg and 250 mg – to be delisted 1 January 2022
- Miconazole (Decozol) oral gel 20 mg per g, 40 g – addition of PSS
- Milrinone (Milrinone-Baxter) inj 1 mg per ml, 10 ml ampoule – new listing and addition of PSS

## Summary of decisions – effective 1 July 2021 (continued)

- Milrinone (Primacor) inj 1 mg per ml, 10 ml ampoule – to be delisted  
1 December 2021
- Neostigmine metilsulfate with glycopyrronium bromide (Max Health) inj 2.5 mg with glycopyrronium bromide 0.5 mg per ml, 1 ml ampoule
  - addition of PSS
- Ondansetron (Ondansetron-Baxter) inj 2 mg per ml, 2 ml ampoule
  - new listing
- Ondansetron (Ondansetron-Claris) inj 2 mg per ml, 2 ml ampoule
  - to be delisted 1 January 2022
- Oral feed (Sustagen Hospital Formula Active (Choc) and (Van)) powder 23 g protein, 65 g carbohydrate and 2.5 g fat per 100 g, can, 840 g
  - price decrease and remove note
- Ornnidazole (Arrow-Ornidazole) tab 500 mg – price increase and addition of PSS
- Oxycodone hydrochloride (OxyNorm) cap immediate release 5 mg, and 10 mg
  - addition of PSS
- Oxycodone hydrochloride (OxyNorm) cap immediate release 20 mg
  - price decrease and addition of PSS
- Picibanil inj 100 mcg vial – change of presentation strength
- Prednisolone (Redipred) oral liq 5 mg per ml, 30 ml – addition of PSS
- Prednisone (Apo-Prednisone) tab 1 mg, 2.5 mg, 5 mg and 20 mg
  - price increase
- Riluzole (Rilutek) tab 50 mg – addition of PSS
- Sodium fusidate [fusidic acid] (Foban) crm 2%, 5 g and oint 2%, 5 g
  - addition of PSS
- Sodium picosulfate (Dulcolax SP Drop) oral soln 7.5 mg per ml, 30 ml
  - new listing with restrictions
- Solifenacin succinate (Solifenacin Mylan) tab 5 mg and 10 mg – price decrease and addition of PSS
- Tranexamic acid (Tranexamic-AFT) inj 100 mg per ml, 5 ml ampoule and 10 ml ampoule – price decrease and addition of PSS
- Travoprost (Travatan) eye drops 0.004%, 2.5 ml – new listing and addition of PSS
- Travoprost (Travopt) eye drops 0.004%, 2.5 ml – to be delisted 1 December 2021
- Valganciclovir (Valganciclovir Mylan) tab 450 mg – price decrease and addition of PSS

## **Summary of decisions – effective 1 July 2021 (continued)**

- Zoledronic acid (Zoledronic acid Mylan) inj 4 mg per 5 ml, vial – price decrease and addition of PSS

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

## Section H changes to Part II

Effective 1 July 2021

### ALIMENTARY TRACT AND METABOLISM

8	LANSOPRAZOLE (↓ price and addition of PSS)			
	Cap 15 mg – 5% DV Dec-21 to 2024 .....	4.20	100	Lanzol Relief
	Cap 30 mg – 5% DV Dec-21 to 2024 .....	5.26	100	Lanzol Relief
9	ACARBOSE (brand change and addition of PSS)			
	Tab 50 mg – 5% DV Dec-21 to 2024.....	8.95	90	Accarb
	Tab 100 mg – 5% DV Dec-21 to 2024.....	15.29	90	Accarb
	Note – Glucobay tab 50 mg and 100 mg to be delisted 1 December 2021.			
14	BISACODYL (↓ price and addition of PSS)			
	Suppos 10 mg – 5% DV Dec-21 to 2024.....	3.69	10	Lax-Suppositories
14	SODIUM PICOSULFATE (new listing)			
	➔ Oral soln 7.5 mg per ml .....	7.40	30 ml	Dulcolax SP Drop
	Restricted			
	Initiation			
	Both:			
	1 The patient is a child with problematic constipation despite an adequate trial of other oral pharmacotherapies including macrogol where practicable and			
	2 The patient would otherwise require a high-volume bowel cleansing preparation.			
20	IRON (AS FERRIC CARBOXYMALTOSE) (amended chemical name)			
	➔ Inj 50 mg per ml, 10 ml vial .....	150.00	1	Ferinject
20	FERROUS SULPHATE SULFATE (amended chemical name)			
	Tab long-acting 325 mg (105 mg elemental).....	2.06	30	Ferrograd
20	FERROUS SULPHATE SULFATE WITH ASCORBIC ACID (amended chemical name)			
	Tab long-acting 325 mg (105 mg elemental) with ascorbic acid 500 mg			
20	IRON (AS SUCROSE) (amended chemical name)			
	Inj 20 mg per ml, 5 ml ampoule .....	100.00	5	Venofer
21	MICONAZOLE (addition of PSS)			
	Oral gel 20 mg per g – 5% DV Dec-21 to 2024 .....	4.74	40 g	Decozol
	➔ Restriction			
	(Brand) indicates a brand example only. It is not a contracted product.			
27	FOLIC ACID (brand change and addition of HSS)			
	Tab 5 mg – 1% DV Dec-21 to 2024.....	5.82	100	Folic Acid Mylan
	Note – Apo-Folic Acid tab 5 mg to be delisted 1 December 2021.			

		Price (ex man. Excl. GST)	\$	Per	Brand or Generic Manufacturer
<b>Changes to Section H Part II – effective 1 July 2021 (continued)</b>					
29	TRANEXAMIC ACID (↓ price and addition of PSS)				
	Inj 100 mg per ml, 5 ml ampoule – <b>5% DV Dec-21 to 2024</b> .....	5.95	5		Tranexamic-AFT
	Inj 100 mg per ml, 10 ml ampoule – <b>5% DV Dec-21 to 2024</b> .....	5.95	5		Tranexamic-AFT
32	ENOXAPARIN SODIUM (↑ price)				
	Inj 20 mg in 0.2 ml syringe .....	31.28	10		Clexane
	Inj 40 mg in 0.4 ml syringe .....	42.49	10		Clexane
	Inj 60 mg in 0.6 ml syringe .....	60.67	10		Clexane
	Inj 80 mg in 0.8 ml syringe .....	80.89	10		Clexane
	Inj 100 mg in 1 ml syringe .....	101.30	10		Clexane
	Inj 120 mg in 0.8 ml syringe .....	125.87	10		Clexane Forte
	Inj 150 mg in 1 ml syringe .....	143.86	10		Clexane Forte
35	FILGRASTIM (addition of PSS)				
	→ Inj 300 mcg in 0.5 ml prefilled syringe – <b>5% DV Dec-21 to 2024</b> .....	96.22	10		Nivestim
	→ Inj 480 mcg in 0.5 ml prefilled syringe – <b>5% DV Dec-21 to 2024</b> (+ price).....	148.58	10		Nivestim
<b>CARDIOVASCULAR SYSTEM</b>					
40	CANDESARTAN CILEXETIL (addition of PSS)				
	Tab 4 mg – <b>5% DV Dec-21 to 2024</b> (+ price).....	2.00	90		Candestar
	Tab 8 mg – <b>5% DV Dec-21 to 2024</b> .....	2.28	90		Candestar
	Tab 16 mg – <b>5% DV Dec-21 to 2024</b> (↓ price).....	3.31	90		Candestar
	Tab 32 mg – <b>5% DV Dec-21 to 2024</b> (↓ price).....	5.26	90		Candestar
41	DOXAZOSIN (↑ price)				
	Tab 2 mg.....	17.35	500		Apo-Doxazosin
	Tab 4 mg.....	20.94	500		Apo-Doxazosin
44	MEXILETINE HYDROCHLORIDE (brand change)				
	Cap 150 mg .....	162.00	100		Teva
	Cap 250 mg .....	202.00	100		Teva
	Note – Mexiletine Hydrochloride USP cap 150 mg and 250 mg are to be delisted 1 January 2022.				
47	ATORVASTATIN (↓ price and addition of PSS)				
	Tab 10 mg – <b>5% DV Dec-21 to 2024</b> .....	6.16	500		Lorstat
	Tab 20 mg – <b>5% DV Dec-21 to 2024</b> .....	9.24	500		Lorstat
	Tab 40 mg – <b>5% DV Dec-21 to 2024</b> .....	14.92	500		Lorstat
	Tab 80 mg – <b>5% DV Dec-21 to 2024</b> .....	26.54	500		Lorstat
49	DOBUTAMINE (addition of PSS)				
	Inj 12.5 mg per ml, 20 ml ampoule – <b>5% DV Dec-21 to 2024</b> .....	61.13	5		Dobutamine-hamelin

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

## Changes to Section H Part II – effective 1 July 2021 (continued)

51	MILRINONE (brand change and addition of PSS) Inj 1 mg per ml, 10 ml ampoule – <b>–5% DV Dec-21 to 2024</b> ..... 71.00 Note – Primacor inj 1 mg per ml, 10 ml ampoule to be delisted 1 December 2021.	10		Milrinone-Baxter
51	BOSENTAN (↓ price and addition of PSS) → Tab 62.5 mg – <b>–5% DV Dec-21 to 2024</b> ..... 119.85 → Tab 125 mg – <b>–5% DV Dec-21 to 2024</b> ..... 119.85	60		Bosentan Dr Reddy's Bosentan Dr Reddy's
		60		

## DERMATOLOGICALS

54	SODIUM FUSIDATE [FUSIDIC ACID] (addition of PSS) Crm 2% – <b>–5% DV Dec-21 to 2024</b> ..... 1.59 Oint 2% – <b>–5% DV Dec-21 to 2024</b> ..... 1.59	5 g		Foban Foban
55	CROTAMITON (addition of PSS) Crm 10% – <b>–5% DV Dec-21 to 2024</b> ..... 3.29	20 g		Itch-Soothe
57	HYDROCORTISONE BUTYRATE (↓ price and addition of PSS) Oint 0.1% – <b>–5% DV Dec-21 to 2024</b> ..... 10.28 Milky emul 0.1% – <b>–5% DV Dec-21 to 2024</b> ..... 12.33	100 g 100 ml		Locoid Locoid Crelo
58	HYDROCORTISONE WITH MICONAZOLE (↓ price and addition of PSS) Crm 1% with miconazole nitrate 2% – <b>–5% DV Dec-21 to 2024</b> ..... 1.89	15 g		Micreme H
58	BETAMETHASONE DIPROPIONATE WITH CALCIPOTRIOL (↓ price and addition of PSS) Gel 500 mcg with calcipotriol 50 mcg per g – <b>–5% DV Dec-21 to 2024</b> ..... 39.35 Oint 500 mcg with calcipotriol 50 mcg per g – <b>–5% DV Dec-21 to 2024</b> ..... 15.90	60 g 30 g		Daivobet Daivobet
59	HYDROCORTISONE BUTYRATE (↓ price and addition of PSS) Scalp lotion 0.1% – <b>–5% DV Dec-21 to 2024</b> ..... 6.57	100 ml		Locoid
59	FLUOROURACIL SODIUM (↓ price and addition of PSS) Crm 5% – <b>–5% DV Dec-21 to 2024</b> ..... 6.95	20 g		Efudix

## GENITO-URINARY SYSTEM

63	SOLIFENACIN SUCCINATE (↓ price and addition of PSS) Tab 5 mg – <b>–5% DV Dec-21 to 2024</b> ..... 2.05 Tab 10 mg – <b>–5% DV Dec-21 to 2024</b> ..... 3.72	30		Solifenacin Mylan Solifenacin Mylan
----	--	----	--	--

## HORMONE PREPARATIONS

65	ZOLEDRONIC ACID (↓ price and addition of PSS) → Inj 4 mg per 5 ml, vial – <b>–5% DV Dec-21 to 2024</b> ..... 18.00	1		Zoledronic acid Mylan
66	PREDNISOLONE (addition of PSS) Oral liq 5 mg per ml – <b>–5% DV Dec-21 to 2024</b> ..... 6.00	30 ml		Redipred

➔ Restriction

(Brand) indicates a brand example only. It is not a contracted product.

		Price (ex man. Excl. GST)	\$	Per	Brand or Generic Manufacturer
--	--	------------------------------	----	-----	-------------------------------------

## Changes to Section H Part II – effective 1 July 2021 (continued)

66	PREDNISONE (↑ price)				
	Tab 1 mg.....	18.58	500		Apo-Prednisone
	Tab 2.5 mg.....	21.04	500		Apo-Prednisone
	Tab 5 mg.....	19.30	500		Apo-Prednisone
	Tab 20 mg.....	50.51	500		Apo-Prednisone

## INFECTIONS

74	AMIKACIN (↓ price and addition of PSS) → Inj 250 mg per ml, 2 ml vial – 5% DV Dec-21 to 2024 .....	199.95	5	<b>DBL Amikacin</b>
77	AZITHROMYCIN (brand change and addition of HSS) → Tab 500 mg – 1% DV Dec-21 to 2024.....	2.57	2	Zithromax
	Note – Apo-Azithromycin tab 500 mg to be delisted 1 December 2021.			
78	AMOXICILLIN WITH CLAVULANIC ACID (brand change and addition of PSS) Inj 500 mg with clavulanic acid 100 mg vial – 5% DV Dec-21 to 2024.....	17.50	10	<b>Amoxiclav multichem</b>
	Inj 1,000 mg with clavulanic acid 200 mg vial – 5% DV Dec-21 to 2024.....	26.90	10	<b>Amoxiclav multichem</b>
	Note – m-Amoxiclav inj 500 mg with clavulanic acid 100 mg vial and inj 1,000 mg with clavulanic acid 200 mg vial to be delisted 1 December 2021.			
81	LINEZOLID (addition of PSS) → Tab 600 mg – 5% DV Dec-21 to 2024 (↓ price).....	276.89	10	<b>Zyvox</b>
	→ Inj 2 mg per ml, 300 ml bottle – 5% DV Dec-21 to 2024 (pack size change).....	155.00	10	<b>Linezolid Kabi</b>
	Note – Linezolid Kabi 1 injection pack to be delisted 1 December 2021.			
83	FLUCONAZOLE (new listing and transfer of HSS) → Inj 2 mg per ml, 50 ml vial – 1% DV Jul-21 to 2022.....	2.80	1	<b>Fluconazole-Baxter</b>
86	ORNIDAZOLE (↑ price and addition of PSS) Tab 500 mg – 5% DV Dec-21 to 2024.....	36.16	10	<b>Arrow-Ornidazole</b>
91	VALGANCICLOVIR (↓ price and addition of PSS) → Tab 450 mg – 5% DV Dec-21 to 2024.....	132.00	60	<b>Valganciclovir Mylan</b>

## MUSCULOSKELETAL SYSTEM

97	NEOSTIGMINE METILSULFATE WITH GLYCOPYRRONIUM BROMIDE (addition of PSS) Inj 2.5 mg with glycopyrronium bromide 0.5 mg per ml, 1 ml ampoule – 5% DV Dec-21 to 2024.....	26.13	10	<b>Max Health</b>
103	BACLOFEN (↑ price and addition of PSS) Inj 2 mg per ml, 5 ml ampoule – 5% DV Dec-21 to 2024 .....	306.82	5	<b>Medsurge</b>

		Price (ex man. Excl. GST)		Brand or Generic Manufacturer
		\$	Per	

## Changes to Section H Part II – effective 1 July 2021 (continued)

103	FEBUXOSTAT (amended restriction criteria – affected criteria shown only)			
	→ Tab 80 mg.....	39.50	28	Adenuric
	→ Tab 120 mg.....	39.50	28	Adenuric
	Restricted			
	Initiation – <b>Gout</b>			
	Both:			
	1. Patient has been diagnosed with gout; and			
	2. Any of the following:			
	2.1 The patient has a serum urate level greater than 0.36 mmol/l despite treatment with allopurinol at doses of at least 600 mg/day and addition of probenecid at doses of up to 2 g per day or maximum tolerated dose; or			
	2.2 The patient has experienced intolerable side effects from allopurinol such that treatment discontinuation is required and serum urate remains greater than 0.36 mmol/l despite use of probenecid at doses of up to 2 g per day or maximum tolerated dose; or			
	2.3 The patient has renal impairment such that probenecid is contraindicated or likely to be ineffective and serum urate remains greater than 0.36 mmol/l despite optimal treatment with allopurinol (see Note); or			
	2.4 The patient has previously had an initial Special Authority approval for benzboromarone for treatment of gout.			

Note: In chronic renal insufficiency, particularly when the glomerular filtration rate is 30 ml/minute or less, probenecid may not be effective. The efficacy and safety of febuxostat have not been fully evaluated in patients with severe renal impairment (creatinine clearance less than 30 ml/minute). No dosage adjustment of febuxostat is necessary in patients with mild or moderate renal impairment. Optimal treatment with allopurinol in patients with renal impairment is defined as treatment to the creatinine clearance-adjusted dose of allopurinol then, if serum urate remains greater than 0.36 mmol/l, a gradual increase of the dose of allopurinol to 600 mg or the maximum tolerated dose.

## NERVOUS SYSTEM

106	RILUZOLE (addition of PSS)			
	→ Tab 50 mg – 5% DV Dec-21 to 2024.....	130.00	56	Rilutek
109	ARTICAINE HYDROCHLORIDE WITH ADRENALINE (new listing)			
	Inj 4% with adrenaline 1:100,000, 1.8 ml dental cartridge			
	Inj 4% with adrenaline 1:200,000, 1.8 ml dental cartridge			
110	LIDOCAINE [LIGNOCAINE] HYDROCHLORIDE (brand change and new listing)			
	Inj 2%, 5 ml ampoule – 1% DV Jul-21 to 2022 .....	8.25	25	Lidocaine-Baxter
	Inj 2%, 20 ml vial – 1% DV Jul-21 to 2022 .....	6.45	5	Lidocaine-Baxter
	Note – Lidocaine-Claris inj 2%, 5 ml ampoule to be delisted 1 January 2022.			
110	MEPIVACAINE HYDROCHLORIDE WITH ADRENALINE (new listing)			
	Inj 2% with adrenaline 1:100,000, 1.8 ml dental cartridge			
	Inj 2% with adrenaline 1:100,000, 2.2 ml dental cartridge			
112	OXYCODONE HYDROCHLORIDE (addition of PSS)			
	Cap immediate-release 5 mg – 5% DV Dec-21 to 2024 .....	1.88	20	OxyNorm
	Cap immediate-release 10 mg – 5% DV Dec-21 to 2024.....	3.32	20	OxyNorm
	Cap immediate-release 20 mg – 5% DV Dec-21 to 2024 (↓ price).....	5.23	20	OxyNorm



(Brand) indicates a brand example only. It is not a contracted product.

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

## Changes to Section H Part II – effective 1 July 2021 (continued)

119	APREPITANT (↓ price and addition of PSS) → Cap 2 × 80 mg and 1 × 125 mg – 5% DV Dec-21 to 2024.....	30.00	3	Emend Tri-Pack
120	CYCLIZINE HYDROCHLORIDE (↓ price and addition of PSS) Tab 50 mg – 5% DV Dec-21 to 2024.....	0.49	10	Nausicalm
120	ONDANSETRON (brand change) Inj 2 mg per ml, 2 ml ampoule .....	1.50	5	Ondansetron-Baxter
	Note – Ondansetron-Claris inj 2 mg per ml, 2 ml ampoule to be delisted 1 January 2022.			
123	LORAZEPAM (addition of PSS) Tab 1 mg – 5% DV Dec-21 to 2024..... Tab 2.5 mg – 5% DV Dec-21 to 2024.....	9.72 12.50	250 100	Ativan Ativan

## ONCOLOGY AGENTS AND IMMUNOSUPPRESSANTS

131	CYCLOPHOSPHAMIDE (addition of PSS) Inj 1 g vial – 5% DV Dec-21 to 2024..... Inj 2 g vial – 5% DV Dec-21 to 2024.....	35.65 71.25	1 1	Endoxan Endoxan
133	AZACITIDINE (↓ price and addition of PSS) → Inj 100 mg vial – 5% DV Dec-21 to 2024.....	75.06	1	Azacitidine Dr Reddy's
143	IMATINIB MESILATE (amended note) Imatinib-AFT is not a registered for the treatment of Gastro Intestinal Stromal Tumours (GIST). The Glivec brand of imatinib mesilate (supplied by Novartis) remains is fully subsidised under Special Authority for patients with unresectable and/or metastatic malignant GIST only, see SA1460 in Section B of the Pharmaceutical Schedule. → Tab 100 mg..... Cap 100 mg – 1% DV Jun-21 to 2023..... Cap 400 mg – 1% DV Jun-21 to 2023.....	2,400.00 58.23 84.79	60 60 30	Glivec Imatinib-Rex Imatinib-Rex
205	PICIBANIL (change of presentation strength) Inj 100 mg mcg vial			

## RESPIRATORY SYSTEM AND ALLERGIES

207	FLUTICASONE PROPIONATE (addition of PSS) Nasal spray 50 mcg per dose – 5% DV Dec-21 to 2024 .....	1.98	120 dose	Flixonase Hayfever & Allergy
-----	--	------	----------	------------------------------

## SENSORY ORGANS

219	DORZOLAMIDE WITH TIMOLOL (↓ price and addition of PSS) Eye drops 2% with timolol 0.5% – 5% DV Dec-21 to 2024.....	2.73	5 ml	Dortimopt
-----	--	------	------	-----------

		Price (ex man. Excl. GST) \$	Per	Brand or Generic Manufacturer
--	--	------------------------------------	-----	-------------------------------------

## Changes to Section H Part II – effective 1 July 2021 (continued)

221 TRAVOPROST (brand change and addition of PSS)  
 Eye drops 0.004% – 5% DV Dec-21 to 2024 ..... 9.75     2.5 ml     Travatan

Note – Travopt eye drops 0.004% to be delisted 1 December 2021.

## VARIOUS

227 GADOTERIC ACID (↓ price)  
 Inj 279.32 mg per ml (0.5 mmol per ml),  
     10 ml prefilled syringe ..... 17.20     1     Dotarem  
 Inj 279.32 mg per ml (0.5 mmol per ml), 15 ml bottle ..... 25.35     1     Dotarem  
 Inj 279.32 mg per ml (0.5 mmol per ml),  
     15 ml prefilled syringe ..... 25.80     1     Dotarem  
 Inj 279.32 mg per ml (0.5 mmol per ml),  
     20 ml prefilled syringe ..... 34.40     1     Dotarem  
 Inj 279.32 mg per ml (0.5 mmol per ml), 10 ml bottle ..... 14.30     1     Dotarem  
 Inj 279.32 mg per ml (0.5 mmol per ml), 20 ml bottle ..... 28.90     1     Dotarem  
 Inj 279.32 mg per ml (0.5 mmol per ml), 5 ml bottle ..... 9.10     1     Dotarem

227 GADOTERIC ACID (pack size change)  
 Inj 279.32 mg per ml (0.5 mmol per ml),  
     10 ml prefilled syringe ..... 172.00     10     Dotarem  
 Inj 279.32 mg per ml (0.5 mmol per ml),  
     15 ml prefilled syringe ..... 258.00     10     Dotarem  
 Inj 279.32 mg per ml (0.5 mmol per ml),  
     20 ml prefilled syringe ..... 344.00     10     Dotarem

Note – Dotarem 10 ml prefilled syringe, 15 ml prefilled syringe and 20 ml prefilled syringe, 1 inj packs to be delisted 1 July 2022.

## SPECIAL FOODS

244 AMINO ACID FORMULA (new listing)  
 ➔ Powder 13.3 g protein, 57 g carbohydrate and  
     24.6 g fat per 100 g, can ..... 43.60     400 g     Alfamino

250 ORAL FEED (↓ price and remove note)  
 ➔ Powder 23 g protein, 65 g carbohydrate and  
     2.5 g fat per 100 g, can ..... 14.00     840 g     Sustagen Hospital  
                                 Formula Active  
                                 (Choc)  
                                 Sustagen Hospital  
                                 Formula Active (Van)

Note: Community subsidy of Sustagen Hospital Formula is subject to both Special Authority criteria and a manufacturer's surcharge. Higher subsidy by endorsement is available for patients meeting the following endorsement criteria; fat malabsorption, fat intolerance or chyle leak.



(Brand) indicates a brand example only. It is not a contracted product.

	Price (ex man. Excl. GST)	\$	Brand or Generic Manufacturer	Per
--	------------------------------	----	-------------------------------------	-----

## Changes to Section H Part II – effective 1 July 2021 (continued)

### VACCINES

- 253 MENINGOCOCCAL B MULTICOMPONENT VACCINE (new listing)  
 ➔ Inj 175 mcg per 0.5 ml prefilled syringe ..... 0.00 1 Bexsero
- Restricted
- Initiation – Infants under one year of age
- Any of the following:
1. up to three doses for patients pre- and post-splenectomy and for patients with functional or anatomic asplenia, HIV, complement deficiency (acquired or inherited), or pre- or post-solid organ transplant; or
  2. up to three doses for close contacts of meningococcal cases of any group; or
  3. up to three doses for child who or has previously had meningococcal disease of any group; or
  4. up to three doses for bone marrow transplant patients; or
  5. up to three doses for person pre- and post-immunosuppression\*
- Initiation – Person is one year of age or over
- Any of the following:
1. up to two doses and a booster every five years for patients pre- and post-splenectomy and for patients with functional or anatomic asplenia, HIV, complement deficiency (acquired or inherited), or pre- or post-solid organ transplant; or
  2. up to two doses for close contacts of meningococcal cases of any group; or
  3. up to two doses for person who has previously had meningococcal disease of any group; or
  4. up to two doses for bone marrow transplant patients; or
  5. up to two doses for person pre- and post-immunosuppression\*
- \*Immunosuppression due to corticosteroid or other immunosuppressive therapy must be for a period of greater than 28 days.

# Index

## Pharmaceuticals and brands

### A

Acarbose .....	8
Accarb .....	8
Adenuric .....	12
Alfamino .....	14
Amikacin .....	11
Amino acid formula .....	14
Amoxicillin with clavulanic acid .....	11
Amoxiclav multichem .....	11
Apo-Doxazosin .....	9
Apo-Prednisone .....	11
Aprepitant .....	13
Arrow-Ornidazole .....	11
Articaine hydrochloride with adrenaline .....	12
Ativan .....	13
Atorvastatin .....	9
Azacitidine .....	13
Azacitidine Dr Reddy's .....	13
Azithromycin .....	11

### B

Baclofen .....	11
Betamethasone dipropionate with calcipotriol .....	10
Bexsero .....	15
Bisacodyl .....	8
Bosentan .....	10
Bosentan Dr Reddy's .....	10

### C

Candesartan cilexetil .....	9
Candestar .....	9
Clexane .....	9
Clexane Forte .....	9
Crotamiton .....	10
Cyclizine hydrochloride .....	13
Cyclophosphamide .....	13

### D

Daivobet .....	10
DBL Amikacin .....	11
Decozol .....	8
Dobutamine .....	9
Dobutamine-hameln .....	9
Dortimopt .....	13
Dorzolamide with timolol .....	13
Dotarem .....	14
Doxazosin .....	9
Dulcolax SP Drop .....	8

### E

Efudix .....	10
Emend Tri-Pack .....	13
Endoxan .....	13
Enoxaparin sodium .....	9

### F

Febuxostat .....	12
Ferinject .....	8
Ferric carboxymaltose .....	8
Ferrograd .....	8
Ferrous sulfate .....	8
Ferrous sulfate with ascorbic acid .....	8
Ferrous sulphate .....	8
Ferrous sulphate with ascorbic acid .....	8
Filgrastim .....	9
Flixonase Hayfever & Allergy .....	13
Fluconazole .....	11
Fluconazole-Baxter .....	11
Fluorouracil sodium .....	10
Fluticasone propionate .....	13
Foban .....	10
Folic acid .....	8
Folic Acid Mylan .....	8
Fusidic acid .....	10

### G

Gadoteric acid .....	14
Glivec .....	13

### H

Hydrocortisone butyrate .....	10
Hydrocortisone with miconazole .....	10

### I

Imatinib mesilate .....	13
Imatinib-Rex .....	13
Iron (as ferric carboxymaltose) .....	8
Iron (as sucrose) .....	8
Iron sucrose .....	8
Itch-Soothe .....	10

### L

Lansoprazole .....	8
Lanzol Relief .....	8
Lax-Suppositories .....	8
Lidocaine-Baxter .....	12
Lidocaine [Lignocaine] hydrochloride .....	12
Lignocaine .....	12
Linezolid .....	11
Linezolid Kabi .....	11
Locoid .....	10
Locoid Crelo .....	10
Lorazepam .....	13
Lorstat .....	9

### M

Medsurge .....	11
Meningococcal B multicomponent vaccine .....	15
Mepivacaine hydrochloride with adrenaline .....	12
Mexiteline hydrochloride .....	9
Miconazole .....	8

# Index

## Pharmaceuticals and brands

Micreme H.....	10	Riluzole.....	12
Milrinone.....	10	S	
Milrinone-Baxter.....	10	Sodium fusidate [Fusidic acid] .....	10
<b>N</b>		Sodium picosulfate .....	8
Nausicalm.....	13	Solifenacin Mylan.....	10
Neostigmine metilsulfate with glycopyrronium bromide .....	11	Solifenacin succinate .....	10
Nivestim .....	9	Sustagen Hospital Formula Active (Choc).....	14
<b>O</b>		Sustagen Hospital Formula Active (Van) .....	14
Ondansetron .....	13	T	
Ondansetron-Baxter .....	13	Tranexamic acid.....	9
Oral feed .....	14	Tranexamic-AFT .....	9
Ornidazole.....	11	Travatan.....	14
Oxycodone hydrochloride.....	12	Travoprost .....	14
OxyNorm .....	12	<b>V</b>	
<b>P</b>		Valganciclovir .....	11
Picibanil.....	13	Valganciclovir Mylan .....	11
Prednisolone.....	10	Venofer.....	8
Prednisone.....	11	<b>Z</b>	
<b>R</b>		Zithromax.....	11
Redipred .....	10	Zoledronic acid .....	10
Rilutek .....	12	Zoledronic acid Mylan .....	10
		Zyvox.....	11

New Zealand  
Permit No. 478

**Permit** 

Pharmaceutical Management Agency

Level 9, 40 Mercer Street, PO Box 10254, Wellington 6143, New Zealand

Phone: 64 4 460 4990 - Fax: 64 4 460 4995 - [www.pharmac.govt.nz](http://www.pharmac.govt.nz)

Email: [enquiry@pharmac.govt.nz](mailto:enquiry@pharmac.govt.nz)

ISSN 1172-3694 (Print)

ISSN 1179-3708 (Online)

Te Kāwanatanga o Aotearoa    New Zealand Government

While care has been taken in compiling this Update, Pharmaceutical Management Agency takes no responsibility for any errors or omissions and shall not be liable to any person for any damages or loss arising out of reliance by that person for any purpose on any of the contents of this Update. Errors and omissions brought to the attention of Pharmaceutical Management Agency will be corrected if necessary by an erratum or otherwise in the next edition of the update.